Loading...
XTSXAVCR
Market cap4mUSD
Dec 24, Last price  
0.06CAD
1D
0.00%
1Q
-66.67%
Jan 2017
-72.73%
Name

Avricore Health Inc

Chart & Performance

D1W1MN
XTSX:AVCR chart
P/E
—
P/S
1.74
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
24.07%
Rev. gr., 5y
72.76%
Revenues
3m
+97.08%
239,271223,586256,243249,042282,2611,459,686305,59283,361005,713156,4671,013,690537,714226,44533,00033,030122,8081,768,3743,485,147
Net income
-701k
L-14.30%
-796,301-378,301-562,090-1,937,735-1,183,009-3,992,659-1,875,565-306,565283,432-733,946-2,200,648-2,819,719-2,613,904-2,736,717-4,136,802-2,105,608-1,173,966-1,708,132-818,228-701,215
CFO
660k
P
-404,716-314,656-371,023-876,722-930,623-3,612,059-673,340-58,663-154,607-539,519-1,484,577-1,927,590-2,064,090-1,767,296-1,725,047-686,407-1,223,396-1,234,154-437,832660,403
Earnings
May 28, 2025

Profile

Avricore Health Inc. engages in the health data and point-of-care technologies business in Canada. It provides HealthTab, a lab-accurate point of care testing platform for pharmacy. The company has strategic partnerships with Shoppers Drug Marts and Abbott. The company was formerly known as Vanc Pharmaceuticals Inc. and changed its name to Avricore Health Inc. in October 2018. Avricore Health Inc. was founded in 1996 and is based in Vancouver, Canada.
URL
https://avricore.com/
IPO date
Jul 31, 2001
Employees
Domiciled in
CA
Incorporated in
CA

Valuation

Title
CAD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122015‑06
Income
Revenues
3,485
97.08%
1,768
1,339.95%
123
271.81%
Cost of revenue
4,126
2,493
1,798
Unusual Expense (Income)
NOPBT
(640)
(725)
(1,676)
NOPBT Margin
Operating Taxes
(45)
38
Tax Rate
NOPAT
(640)
(679)
(1,714)
Net income
(701)
-14.30%
(818)
-52.10%
(1,708)
45.50%
Dividends
Dividend yield
Proceeds from repurchase of equity
42
254
2,404
BB yield
-0.82%
-16.22%
Debt
Debt current
40
40
40
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
(247)
(591)
(1,973)
Cash flow
Cash from operating activities
660
(438)
(1,234)
CAPEX
(1,022)
(1,199)
(140)
Cash from investing activities
(1,047)
(1,209)
(140)
Cash from financing activities
42
254
3,085
FCF
(1,073)
(1,831)
(1,907)
Balance
Cash
287
631
2,013
Long term investments
Excess cash
112
542
2,007
Stockholders' equity
2,009
1,964
2,197
Invested Capital
1,937
1,411
230
ROIC
ROCE
EV
Common stock shares outstanding
99,559
97,859
92,611
Price
0.32
96.88%
0.16
68.42%
Market cap
30,826
108.03%
14,818
158.03%
EV
30,235
12,845
EBITDA
(220)
(542)
(1,658)
EV/EBITDA
Interest
6
5
38
Interest/NOPBT